Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Yumanity Therapeutics (Nasdaq: YMTX), a biopharmaceutical company focused on neurodegenerative diseases, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Yumanity Therapeutics (Nasdaq: YMTX), a biopharmaceutical company focused on neurodegenerative diseases, will present at the H.C. Wainwright Global Life Sciences Conference. CEO Richard Peters, M.D., Ph.D., will deliver the presentation, available on-demand starting March 9 at 7:00 a.m. EST on the conference portal and the company website. Yumanity is currently developing YTX-7739, a therapy in Phase 1 trials for Parkinson's disease, and has a diverse pipeline addressing various neurodegenerative conditions. More details can be found at yumanity.com.
Details
News Market Reaction – YMTX
The recorded move for YMTX in the trading session of this news was -1.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference.
The presentation will be available on-demand via the conference portal and through the Company's website at yumanity.com/events beginning March 9, starting at 7:00am EST.
About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.
Contacts
Investors:
Burns McClellan, Inc.
John Grimaldi
jgrimaldi@burnsmc.com
(212) 213-0006
Media:
Burns McClellan, Inc.
Ryo Imai / Robert Flamm, Ph.D.
rimai@burnsmc.com / rflamm@burnsmc.com
(212) 213-0006
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.